Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.
Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.
Clinical Pearls:
The presence of visceral metastatses is a poor prognostic indicator for men with prostate cancer.
Seven of the 8 patients enrolled in the trial so far have experienced prolonged disease stability.
One patient with liver metastases saw a regression of his liver disease in 12 weeks of treatment.
Researchers of this trial are characterizing circulating tumor cells and large oncosomes in the hopes of one day eliminating the need for needle biopsies for men with prostate cancer.
